Bevacizumab is employed cautiously in patients with multifocal glioblastomas rather than single glioblastomas because of a fear, based on unconfirmed preclinical data, that bevacizumab can increase the invasive tumor phenotype.
Glioblastoma has a highly infiltrative growth pattern that increases in later disease stages. Tumor cells infiltrate the brain, proliferate, and form tumor nodules at multiple locations. Glioblastoma cells secrete vascular endothelial growth factor A (VEGF-A), which induces the formation of a dysfunctional vascular system in the tumor.
Treatment with bevacizumab (Avastin or a biosimilar), which targets VEGF-A, inhibits neovascularization, and initially leads to increased tumor profusion due to improved oxygenation of the tumor tissue. However, ongoing treatment with bevacizumab leads to regression of tumor vasculature. In clinical practice, however, bevacizumab is employed cautiously in patients with multifocal glioblastomas rather than single glioblastomas because of a fear, based on unconfirmed preclinical data, that bevacizumab can increase the invasive tumor phenotype.
In order to clarify whether bevacizumab should be applied to patients with multifocal glioblastomas, the authors of a recent study, published in International Journal of Molecular Sciences, performed a retrospective data analysis of patients with glioblastomas who were treated at University Hospital Frankfurt between April 2008 and March 2016.
All patients (n = 164) with multifocal glioblastomas were compared to a matched control cohort with single glioblastomas; all patients received bevacizumab in the relapse situation. The investigators compared response rate, progression-free survival, overall survival, and relapse between the groups.
In patients with multifocal glioblastoma, a partial response (PR) was observed as best response 11 patients, stable disease (SD) in 2 patients, mixed response (MR) in 1 patient, and progressive disease (PD) in 2 patients. In the single glioblastoma cohort, PR was observed as best response in 9 patients, SD in 3 patients, MR response in 1 patient, and PD in 3 patients. No significant difference in PFS or OS was observed between the 2 groups. However, there was a trend for shorter OS in the multifocal glioblastoma group. Median PFS was 21 weeks for patients with multifocal glioblastoma, and 23.5 weeks for their matched controls. Median OS was 33 weeks in the multifocal glioblastoma group, and 43.5 weeks in the control group.
To examine whether bevacizumab led to a more infiltrative tumor phenotype, the investigators explored the share of new lesions on the patients’ last magnetic resonance imaging showing progression before the start of bevacizumab and at progression under bevacizumab therapy in both groups. There was no significant difference between the 2 groups in the frequency of new lesions.
The researchers conclude that bevacizumab should be given to patients with multifocal glioblastoma where no reasonable therapy alternative exists. “These patients often are in a critical condition and further clinical deterioration would make many patients considerably dependent on caregivers. Delaying this deterioration is of high concern both to the patients and their caregivers, even if no prolongation of survival can be achieved,” say the authors.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Duke Publishes Recommendations for Developing CGT Biosimilars
October 9th 2024Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex biologics limit competition, requiring policies that support the development of biosimilars to enhance affordability and patient access.